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Summary 9 
Despite decades of research many aspects of the biology of Mycobacterium tuberculosis 10 
remain unclear and this is reflected in the antiquated tools available to treat and prevent 11 
tuberculosis and consequently this disease remains a serious public health problem. 12 
Important discoveries linking M. tuberculosis’s metabolism and pathogenesis has 13 
renewed interest in this area of research. Previous experimental studies were limited to 14 
the analysis of individual genes or enzymes whereas recent advances in computational 15 
systems biology and high throughput experimental technologies now allows metabolism 16 
to be studied on a genome scale. Here we discuss the progress being made in applying 17 
system level approaches to studying the metabolism of this important pathogen. The 18 
information from these studies will fundamentally change our approach to tuberculosis 19 
research and lead to new targets for therapeutic drugs and vaccines. 20 
Introduction 21 
Tuberculosis (TB) is a disease which plagued ancient Egyptians and still remains a major 22 
threat to human health thousands of years later. The control of tuberculosis has been 23 
significantly hindered by the limited resources available for the prevention and treatment 24 
of tuberculosis. A truly effective vaccine is lacking as the 90 year old Mycobacterium 25 
 2 
bovis bacillus Calmette-Guerin live attenuated vaccine is not universally protective and 1 
does not produce immunity against re-infection or reactivation. Lengthy (6-9 months) and 2 
complex (three or more different drugs) treatment is required using currently available 3 
anti-TB drugs. The economic and logistic burden of administering these drug regimens in 4 
industrially undeveloped countries where TB is most prevalent is enormous and 5 
combined with poor patient compliance are important factors in the emergence of drug 6 
resistant TB isolates which are causing ongoing epidemics.  These factors underscore the 7 
urgent need for the development of novel and effective therapeutics and vaccines and 8 
new approaches will be required to achieve these goals.  9 
Mycobacterium tuberculosis is an unusual bacterial pathogen which has the remarkable 10 
ability to cause both acute life threatening disease and also clinically latent infections 11 
which can persist for the lifetime of the human host. Unlike many pathogens M. 12 
tuberculosis does not rely on the production of specific toxins to cause disease but rather 13 
the secret of this bacterium’s great success seems to be the ability to adapt and survive 14 
within the changing and adverse environment provided by the human host during the 15 
course of an infection. It is becoming apparent that key to this adaptation is the metabolic 16 
reprogramming of M. tuberculosis during both the acute and chronic phase of TB disease 17 
and therefore a more complete understanding of mycobacterial metabolism remains a 18 
major goal of TB research.  19 
Whilst recent increases in research funding has progressed our understanding of the basic 20 
biology of M. tuberculosis this has not yet impacted on the global TB trends which 21 
remain at staggering levels. A possible reason why it has been difficult to translate basic 22 
research into effective strategies for combating tuberculosis is that TB research has until 23 
recently, focused on studying individual parameters in isolation which can consequently 24 
result in an overestimation of the importance of these factors. This effect may be 25 
particularly profound for a persistent pathogen such as M. tuberculosis which lacks 26 
classical virulence factors. The systems biology framework which investigates the 27 
dynamic interactions of many components provides an alternative and complementary 28 
strategy to the more traditional reductionist approaches to TB research. The central 29 
component of all systems biology approaches is a mathematical model which instantiates 30 
 3 
knowledge about a particular system that can be used to provide a scaffold for the 1 
integration and interpretation of “omic” scale datasets but is also capable of generating 2 
novel hypotheses and predictions that can be experimentally tested in an iterative cycle of 3 
hypothesis generation, prediction and model refinement (Fig. 1). 4 
Metabolic model building 5 
The ultimate goal of system biology approaches to studying TB is to construct a complete 6 
model of infection incorporating both the pathogen and host, but this is currently 7 
infeasible as the information about the different components to be included in the model 8 
is lacking. Studies with other organisms have demonstrated that metabolism is, by far, the 9 
best understood cellular network and is thereby an excellent starting point for a systems-10 
based approach 1-3.  11 
However, metabolism is complex. Even the simplest organisms synthesize many 12 
hundreds of metabolites connected by a similar number of enzyme-catalyzed reactions. 13 
Each reaction is described by a set of kinetic parameters (e.g. Km, Vmax) which, in 14 
combination with substrate/product concentrations, determine its rate. Although Km 15 
values are constants (for a particular substrate/product combination) and may be 16 
determined experimentally, intracellular concentrations of substrate, products and 17 
enzyme (influencing Vmax) vary over wide ranges and are not easily measured. Even a 18 
single enzyme reaction is therefore a highly dynamic system; and systems of just a few 19 
reactions steps are usually mathematically described by a set of ordinary differential 20 
equation with a large number of parameters and variables whose values are extremely 21 
challenging to measure experimentally.  Kinetic models have therefore only been applied 22 
to the dynamics of small well-defined systems, such as glycolysis in Escherichia coli 4 23 
that are very far from being genome-scale.  24 
However, it is relatively straightforward to generate a metabolic network that describes 25 
the biochemical reactions that an organism is predicted to be capable of performing, in 26 
terms of stoichiometric formulas. The genome annotation predicts all those genes 27 
encoding enzymes that are readily linked to databases describing the predicted 28 
 4 
biochemical conversions performed by these enzymes. These stoichiometric reactions can 1 
then be incorporated into pathways that may be integrated into a network to construct a 2 
genome-scale metabolic network that effectively describes the chain of reactions 3 
responsible for inputting nutrients and transforming them into the biomass of the cell, 4 
waste products and energy.  5 
On their own genome-scale metabolic networks are essentially descriptive, describing the 6 
set of metabolic reactions and their connectivity but cannot actually simulate any 7 
metabolic process. To do that they must incorporate metabolite concentrations and, for 8 
dynamic systems, all the kinetic parameters discussed above which is infeasible at a 9 
genome scale. However, if a critical assumption is made, that all metabolite 10 
concentrations are held constant, then the underlying dynamics are hugely simplified and 11 
the system may be solvable. Consider the simple set of stoichiometric conversions, A → 12 
2 B → C + D. If this is a dynamic system then knowing the concentration of A tells us 13 
nothing about the concentrations of B, C or D without knowledge of the detailed kinetic 14 
parameters. Yet if the concentrations of A, B, C and D are unchanging (the system is at 15 
steady-state) then the rate of flux from A → 2 B must equal the rate of flux from 2 B → 16 
C + D so knowing the concentration of A (or the flux towards A) uniquely determines the 17 
concentration (or the fluxes) of all the downstream metabolites. Steady state systems are 18 
thereby described by far fewer parameters and variables than dynamic systems. 19 
Of course a genome scale model is far more complex than the above system but the entire 20 
set of stoichiometric conversions for an organism is available from its genome annotation 21 
and standard biochemical literature. It is therefore possible to build a model consisting of 22 
all the stoichiometric reactions predicted by the annotation and link these pathways and 23 
networks connected by flux values between each reaction. Such a network can be 24 
incorporated into a mathematical model that, once parametrized by measurements such as 25 
substrate uptake or biomass production rates, can be solved by standard linear algebra 26 
tools (rather than the differential calculus required by kinetic models). However, because 27 
metabolic networks contain multiple branch points and parallel pathways there is not a 28 
unique solution but a vast space of possible solutions (the system is underdetermined). It 29 
is therefore necessary to apply constraint based approaches which reduce the solution 30 
 5 
space and thereby predict metabolic capabilities or internal fluxes 5-10. Flux balance 1 
analysis (FBA) uses the procedure of optimization to reduce the solution space (for a 2 
review of FBA we recommend11,12; whereas metabolic flux analysis (MFA) applies 3 
additional measurements as constraints. The application of both of these methods to M. 4 
tuberculosis will be discussed below.  5 
There are of course limitations to these approaches such as the requirement for steady or 6 
quasi-steady state conditions. Also, since no consideration is made of either 7 
transcriptional, translational, metabolic regulation or enzyme kinetics the predictive 8 
capabilities of constraint based models are limited to situations when these factors are not 9 
significantly influencing reaction rates 3. Nevertheless, this approach has been 10 
successfully applied to predict the metabolic capabilities of many different cellular 11 
systems 5-10 and has also been used in metabolic engineering13,14.  12 
Metabolism of M. tuberculosis 13 
Application of metabolic modeling approaches to M. tuberculosis is aided by the fact that 14 
metabolism is a reasonably well studied system even in mycobacteria. Moreover, 15 
metabolism has been shown to be involved in the virulence of M. tuberculosis, playing a 16 
key role in the development and maintenance of both acute and persistent TB infections 17 
15-17
. It is perhaps not surprising therefore that several modeling efforts in tuberculosis 18 
have focused on metabolism.  19 
Much of what is known about metabolism in M. tuberculosis has been gleaned from 20 
conventional biochemical and molecular studies over many decades. The pathogen 21 
appears typical of bacteria of the Actinomycetales order, with a predominantly aerobic 22 
metabolism that is able to catabolize a wide range of substrates to generate biomass and 23 
energy. The genome encodes all the enzymes of the Embden-Meyerhof-Parnas pathway 24 
(EMP) and pentose phosphate pathway (PPP) and has a complete, or nearly complete 25 
TCA cycle (see below). The pathogen also encodes a functional glyoxylate shunt as well 26 
as several enzymes connecting the TCA cycle and glycolysis that may be used for either 27 
anaplerosis or gluconeogenesis.  28 
 6 
There are however several features of central metabolism in M. tuberculosis that appear 1 
to be unusual. Although the link between glycolysis and the TCA cycle is complete in M. 2 
tuberculosis, the closely related pathogen, M. bovis, lacks a functional pyruvate kinase 3 
and is therefore unable to deliver sugars from glycolysis to the TCA cycle and thus is 4 
unable to utilize carbohydrates as the sole carbon source18. This function is therefore 5 
unnecessary in vivo as this pathogen causes very similar disease in humans to M. 6 
tuberculosis. The role of isocitrate lyase has been intensively studied since the 7 
demonstration that both of the isocitrate lyase genes encoded by this pathogen, icl1 and 8 
icl2 (although some strains only have icl1) play an essential role in virulence 15,16. This 9 
finding has been generally interpreted to be due to this enzymes role in the glyoxylate 10 
shunt and a metabolic shift in the principal carbon source from carbohydrates to fat in the 11 
host. However the role of the isocitrate lyases maybe more complex than just fat 12 
catabolism as these enzymes also function as methyl citrate lyases in the methyl citrate 13 
cycle 19. In addition, it has also been demonstrated that the glyoxylate shunt functions 14 
concurrently with an oxidative TCA cycle which is completed by an anaerobic α-15 
ketoglutarate ferredoxin oxireductase (KOR)20. The TCA cycle also seems to be atypical 16 
since α-ketogluterate dehydrogenase (KDH) activity has not be detected. It has been 17 
proposed that M. tuberculosis can either complete the oxidative TCA using KOR, an 18 
enzyme usually associated with the reductive TCA cycle or use an alternative pathway 19 
from α-ketoglutarate to succinate via succinic semialdehyde20,21. Fig. 2 illustrates the 20 
central metabolic pathways of M. tuberculosis, as understood in 2010.   21 
Experimental systems  22 
Systems biology is an iterative procedure of experimental data acquisition, model 23 
building, hypothesis generation and experimental verification (Fig. 1). One of the 24 
constraints upon this approach surrounds the experimental basis of this work. Models 25 
should be developed and validated with accurate and reproducible data, which can be 26 
obtained from standard high throughput methods such as transcriptomics, proteomics and 27 
metabolomics. However, it is important to note that the mathematical underpinning of 28 
flux-based predictions derived from modeling approaches such as FBA or MFA assume 29 
that the system is in metabolic steady-state; which can usually only be met by growing 30 
 7 
the organism in steady state (typically in a chemostat or batch cultivated cells in the 1 
exponential growth phase where the growth rate is maximal) and flux-based predictions 2 
are only strictly valid for these systems. Determination of substrate utilization and 3 
biomass productions rates are also essential for most flux-based predictions so it is 4 
usually necessary to grow the test organism in defined media with simple and readily 5 
assayable carbon and nitrogen sources.  6 
Our group has developed a system for growing mycobacteria in a carbon limited 7 
chemically defined minimal medium and demonstrated that biomass composition of the 8 
pathogen is a function of the growth rate 22. This adds a further level of complexity to M. 9 
tuberculosis models as, to model the organisms growing at different growth rates, 10 
alternative biomass formulae must be incorporated.   11 
However, it should be emphasized that many systems-based studies of metabolism do not 12 
depend on the steady-state assumption. Indeed, systems-based investigations into the 13 
intracellular metabolism of pathogens can be performed using model free approaches 23-14 
25
.  15 
Modeling the metabolism of M. tuberculosis 16 
The first M. tuberculosis constraint based model was constructed by Raman et al (2005) 17 
and consisted of all the reactions in mycolic acid synthesis 26. This sub-model of 18 
metabolism was composed of 219 reactions which involved 197 metabolites, catalysed by 19 
28 enzymes. FBA was used to simulate mycolic acid metabolism and to identify potential 20 
drug targets in these pathways. The study illustrates the use of optimization in FBA. As 21 
already discussed, FBA solves the excess solution space problem by finding the flux 22 
solution of the network that reaches the optimal value of the ‘objective function’. 23 
Deciding on an appropriate objective function is a perquisite for the successful 24 
application of FBA. Objective functions include: maximization or minimization of ATP 25 
production; maximization of redox potential; maximization of the rate of synthesis of a 26 
particular product, or minimization of nutrient uptake. But the most commonly used 27 
objective function in FBA is maximization of growth rate, which of course makes the 28 
 8 
assumption that microbial cells do indeed maximize their growth rate. Although this 1 
assumption could of course be criticized on many grounds, the use of a  objective 2 
function that maximizes growth rate or biomass formation has been shown to result in a 3 
good predictive accuracy in several experimental systems, including nutrient limited 4 
chemostat culture of E. coli 27. Its use is more problematic for slow growing pathogens, 5 
such as M. tuberculosis, since it is not at clear that these organisms do indeed maximize 6 
their growth rate. Ramen et al (2005) used two objective functions that optimized the 7 
production of mycolic acids. The first, termed C1, optimized production of only the most 8 
abundant mycolate; whereas the objective function C2 maintained the known ratios of 9 
different mycolates.  To test the predictive accuracy of these objective functions in silico 10 
deletions were performed and compared to transposon site hybridization mutagenesis 11 
data. The highest predictive accuracy was obtained with the objective function C1. FBA 12 
identified 16 essential genes in this study and this primary list was then filtered to remove 13 
any genes encoding proteins which were complemented by homologues and also those 14 
with close homologues in the human proteome. This feasibility analysis identified seven 15 
potential drugs targets for anti-TB drug design. 16 
Although targeting a small sub-system such as mycolic acid synthesis can yield valuable 17 
information on specific pathways, it has limited value in elucidating the metabolic 18 
capability of M. tuberculosis. This latter objective is best approached by constructing a 19 
genome-scale networks of metabolism 28,29. Two independent genome scale models of M. 20 
tuberculosis have been published to date (GSMN-TB and iNj661) using different 21 
reconstruction and validation approaches. The first published genome scale network was 22 
built by our group using Streptomyces coelicolor as a starting model 28. Orthology 23 
relationships were mapped between the related species using the KEGG databases and 24 
this preliminary model was further supplemented with data from the BioCyc database. 25 
This automatic process, however accounted for only 57% of the final model. The 26 
remaining model was reconstructed by labour intensive manual curation based upon 27 
primary research publications, textbooks and review articles and also by picking the 28 
brains of experts in the field. The final model utilized two biomass formulations which 29 
were derived from published data of cell composition obtained from a variety of sources 30 
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including our own chemostat-derived data obtained from fast and slow-growing BCG. 1 
BIOMASS 1 reflects the actual macromolecular composition of in vitro-grown M. 2 
tuberculosis; whereas BIOMASSe consisted of only those cellular components, such as 3 
DNA, RNA, protein, co-factors and cell wall skeleton, that were considered to be 4 
essential for in vitro growth. The advantage of having these two biomass formulations is 5 
that the model could be used to predict gene essentiality both in vitro (with the minimal 6 
BIOMASSe as the objective function) and in vivo (with the more complete BIOMASS 1 7 
as the objective function).     8 
The final functional genome scale metabolic network of M. tuberculosis (GSMN-TB) 9 
consisted of 739 metabolites participating in 849 reactions and involves 726 genes (Fig. 10 
1). The model is freely available as both an excel file or in sbml format; and is accessible 11 
via a user friendly web tool for constraint-based simulations 12 
(http://sysbio.sbs.surrey.ac.uk/tb/). FBA-based predictions of in vitro gene essentiality 13 
using BIOMASSe as the objective function correlated had a good correlation with 14 
experimental data obtained by global transposon mutagenesis 30, with an overall 15 
predictive accuracy of 78% 28.  16 
Quantitative validation of the model was performed using data from continuous culture 17 
chemostat experiments 28. The model predicted a lower rate of glycerol consumption than 18 
the experimentally determined values. A plausible explanation for the discrepancy was 19 
that, in addition to consumption of glycerol, the tubercle bacillus also utilized oleic acid 20 
released from hydrolysis of the Tween 80 dispersal agent present in the media. Opening 21 
an additional oleic acid transport flux corrected this discrepancy and unpublished data 22 
from our laboratory has confirmed that Tween 80 is indeed consumed in these 23 
experiments. The success of the approach also demonstrated that growth rate 24 
optimization was an appropriate objective function for M. tuberculosis at least in these in 25 
vitro conditions.  26 
The second genome scale reconstruction of M. tuberculosis was carried out starting with 27 
the genome annotation and then using several databases combined with manual curation 28 
and yielded 939 reactions, catalysed by 543 enzymes encoded by 661 genes29 (Fig. 1). 29 
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Although silicon iNj661 weighs in with 90 more reactions and less genes than the 1 
GSMN-TB the percentage of orphan reactions is approximately 20% in both networks 2 
suggesting that iNj661 has an expanded coverage. However, whilst iNj661 was very good 3 
at predicting the growth rate of M. tuberculois in different media this model had a 4 
relatively poor predictive accuracy for experimental essentiality data (55%) as compared 5 
with GSMN-TB and is also limited by having only one biomass formulation.  6 
Building upon the work described by Ramen et al (2005) hard-coupled reaction (HCR) 7 
sets were calculated for the iNj66I model in order to predict novel drug targets on a 8 
genome scale 29. Hard coupling reaction (HCR) sets are generated by a method which 9 
does not require an objective function and therefore overcomes any bias introduced by 10 
using a specific objective function to constrain the solution space. HCR’s are groups of 11 
reactions which, due to mass conservation and connectivity constraints, must operate in 12 
unison. This strategy identified known and also potential new drug targets which require 13 
further analysis.  14 
Application of genome-scale models to provide system-level insights into metabolism 15 
Genome-scale models can also provide novel insights and predictions that are not readily 16 
apparent from a consideration of individual reactions and pathways. Model predictions 17 
can be structural, depending only on the network connectivity between metabolites (e.g. 18 
FBA-based gene/substrate essentially predictions), or flux-based. The latter (e.g. 19 
predictions of internal fluxes, growth or substrate utilization rates) are usually generated 20 
by methods such as FBA and MFA and depend on the steady-state assumption and are 21 
thereby strictly applicable only to experimental systems in which this condition is 22 
satisfied (see above). Most gene essentiality predictions are structure-based and can yield 23 
some non-intuitive surprises. For instance, the gene encoding isocitrate lyase is 24 
(correctly) predicted to be essential for growth of fatty acids, since the product of their 25 
beta oxidation, acetate, can only be incorporated into biomass via the carbon-conserving 26 
glyoxylate shunt. However, the gene is not predicted to be essential for growth on 27 
complex fats, such as phospholipids and triglycerides, as sole carbon source. The 28 
explanation is apparent through examination of the flux solution. The shunt is no longer 29 
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required because oxidation of these fats yields glycerol in addition to acetate, and 1 
glycerol can be incorporated to generate biomass without operation of the shunt. That the 2 
ICL gene is essential for growth in vivo suggests that either triglycerides and 3 
phospholipids are not in vivo substrates for M. tuberculosis, or, for unknown reasons, 4 
only the acetate product of their oxidation is available for incorporation into biomass.     5 
As an example of a useful flux-based prediction, flux variability analysis (FVA) was 6 
performed to assess the in silico metabolic response of M. tuberculosis to slow growth 7 
(Fig. 3) on Roisin’s media with glycerol as sole carbon source. FVA is a variant of FBA 8 
which, instead of finding a single optimal solution, computes the range of fluxes in each 9 
reaction that are compatible with optimization of the objective function. The FVA 10 
predicted that whereas the relative fluxes through most reactions would be similar 11 
between slow and fast growth rate, a significant relative increase in flux through the 12 
isocitrate lyase reaction was expected at slow growth rate (Fig. 3); leading to the 13 
hypothesis that isocitrate lyase was involved in mycobacterial survival at slow growth 14 
rates. This was surprising since the glyoxylate shunt was not thought to be involved in 15 
catabolism of a 3 carbon compounds (such as glycerol) at any growth rate. However, 16 
experimental measurement of isocitrate lyase enzyme activity at both growth rates in the 17 
chemostat did indeed demonstrate increased isocitrate lyase activity at slow growth rate, 18 
which is consistent with the hypothesis that the glyoxylate shunt is involved in 19 
maintenance of slow growth. We are currently investigating this hypothesis further using 20 
13C-MFA (Fig.4) but the finding may also have relevance to the demonstration that 21 
isocitrate lyase is essential for survival of M. tuberculosis in vivo 15-16,31,32.  22 
Using models to interrogate genome annotation 23 
Genome-scale networks are usually constructed initially from genome annotation and are 24 
thereby subject to errors in that annotation. However, the metabolic model scrutinizes the 25 
metabolic component of genome annotation at a system level for functionality and can 26 
thereby be used to find pathway holes or inconsistencies in the annotation. There are 27 
several ‘orphan reactions’ in GSMN-TB, that is reactions that are required for network 28 
functionality but for which there is no annotated M. tuberculosis gene predicted to 29 
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perform that function. For example, sulfolipid synthesis in M. tuberculosis generates the 1 
metabolite adenosine 3',5'-bisphosphate (PAP in the model) which will accumulate and 2 
thereby become toxic (unbalanced in the model) if it is not catabolized. The model is 3 
therefore infeasible unless the reaction catalyzed by the enzyme 3',5'-bisphosphate 4 
nucleotidase (which converts the metabolite to AMP and inorganic phosphate) is included 5 
in the network, as an orphan reaction. Examining model feasibility thereby generates 6 
clues to incomplete or incorrect genome annotation and may even provide novel drug 7 
targets that are not apparent in the genome annotation.   8 
In silico models also allow genome annotation to be scrutinized by systems-based 9 
experimental data. For example, the route for glycerol utilization is generally assumed to 10 
proceed via glycerol kinase (encoded by glpK) followed by dehydrogenation ; however, 11 
the genome annotation of M. tuberculosis includes several alcohol dehydrogenases that 12 
could be involved in an alternative uptake pathway whereby glycerol is first oxidized by 13 
glycerol dehydrogenase before being phosphorylated (this pathway is annotated in the 14 
KEGG M. tuberculosis pathway map). However, incorporation of this pathway into the 15 
initial GSMN-TB model led to the prediction that the gene glpK  is dispensable for 16 
growth on media with glycerol as sole carbon source. Global mutagenesis data 17 
demonstrated that glpK was in fact essential for growth on glycerol as sole carbon source, 18 
which was confirmed by construction of a glpK knock-out mutant 33. This information 19 
was incorporated into a refined GSMN-TB model in which the annotated alcohol 20 
dehydrogenases does not provide an alternative glycerol uptake pathway.  21 
In this way, genome-scale models can be used to interrogate and correct genome 22 
annotations and the resulting consensus are used to update both model and genome 23 
annotation. 24 
Use of genome-scale models to integrate and interpret functional genome data and 25 
predict metabolic states 26 
The functional genomics revolution has provided the means to generate high-throughput 27 
transcriptomic, proteomic and metabolic datasets but one of the challenges of systems 28 
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biology is to use these datasets to predict the metabolic state of a cell. Transcriptomics is 1 
often the most readily available dataset and therefore several researchers have developed 2 
methods that use genome-scale models to interrogate transcriptome data and predict 3 
aspects of the corresponding metabolic state. However, there are a number of problems 4 
with this approach as the mapping between transcriptome and metabolic flux will be 5 
affected by factors (e.g. post-transcriptional control) that are not measured in 6 
transcriptome experiments. Nevertheless, a number of structural or flux-based approaches 7 
have been developed that use models to interrogate transcriptome data. The simplest 8 
structural method is to use the model as a scaffold and then simply overlay the 9 
transcriptomic data of genes encoding metabolic enzymes onto the reactions catalyzed by 10 
those genes in a network.  However, this approach does not utilize the systems properties 11 
of the networks and thereby generates pathway-centric interpretations. A more 12 
sophisticated method is the reporter metabolites approach which utilizes bi-partite graph 13 
analysis to associate genes with metabolites within a metabolic network and identify 14 
focal points of metabolism: network nodes that appear to be most affected by 15 
differentially expressed (enzyme-encoding) genes 34. We have recently developed a 16 
related method, Differential Producibility Analysis (DPA), which uses FBA to probe 17 
metabolite connectivity and identify similar focal points of metabolism. The method was 18 
used to extract metabolic signals from the transcriptional response of M. tuberculosis to 19 
the macrophage 35 and predicted a general slowing down of central metabolism together 20 
with a remodeling of the bacterial surface as the pathogen adapts to its intracellular 21 
environment.  22 
Several flux-based methods have also been developed. The challenge with these 23 
approaches is that there is not a linear relationship between the level of mRNA encoding 24 
an enzyme and the metabolic flux through the reactions encoded by that enzyme. 25 
Nevertheless, approaches have recently been developed that attempt to predict metabolic 26 
state of organisms including M. tuberculosis from transcriptome data 36 37 38. In the M. 27 
tuberculosis study a large compendium of gene expression data from the tubercule 28 
bacillus growing in a variety of different conditions was used to constrain the MAP sub-29 
model and also GSMN-TB 37. Fluxes were constrained using a function that was based on 30 
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the level of transcript obtained for the gene encoding that enzyme in each experiment and 1 
this was used to limit the maximal flux through each enzymatic reaction.  As the focus of 2 
the study was to predict impact on fatty acid metabolism, both total mycolic acid 3 
production and biomass production were used as objective functions. This ‘E-flux’ 4 
method applied to either the GSMN-TB or MAP correctly predicted that seven of the 5 
eight mycolic acid inhibitors tested in the experimental data negatively modulated 6 
mycolic acid metabolism regardless of which objective function was used. The study also 7 
predicted that several other novel compounds had an impact on mycolic acid metabolism. 8 
The validity of these predictions awaits further experimental testing. 9 
Use of models to identify drug targets 10 
Both the currently available genome-scale M. tuberculosis metabolic networks correctly 11 
identified the target of several anti-tuberculous drugs (e.g. isoniazid) as essential genes 12 
(e.g. inhA). Systems level approaches have also been applied in the drug discovery 13 
process 39 and will undoubtedly facilitate the development of novel anti-TB therapeutics. 14 
Raman et al (2008) have developed a very useful framework for drug discovery which 15 
incorporates the three published M. tuberculosis metabolic models as part of a 16 
comprehensive and integrated scheme for drug identification. TargetTB imposes 17 
sequential filters on an initial list of essential genes (a structural prediction) in order to 18 
generate several shortlists of putative drug targets 40. The first list was generated by 19 
combining data from a protein-protein interactome and FBA studies using both the 20 
available genome scale models (iNj661, GSMN-TB) and also the mycolic acid pathway 21 
(MAP) sub-model. This list was then filtered using sequence analysis to remove genes 22 
with homologues in humans; structural analysis to remove targets with similar binding 23 
sites to human proteins. The process identified 622 putative drug targets including several 24 
known and proposed candidate drug targets thereby validating the method. Further 25 
filtering generated a short list of broad spectrum antibacterial, TB specific targets and 26 
also candidate targets which could be important for treating persistent TB (216 targets).  27 
As an alternative to the above approaches which predict reactions as drug targets by 28 
evaluating their effects on metabolism, Kim et al (2009) 41 used a metabolite-centric 29 
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approach to identify potential candidate drug targets in a number of pathogens including 1 
M. tuberculosis. Using constraint based flux analysis of the iNj661 model, essential 2 
metabolites were identified as metabolites which resulted in zero growth when removed 3 
from the model using growth rate as the objective function. Chokepoint analysis 4 
identifies enzymes that uniquely produce and/or consume a particular metabolite. 5 
Metabolites which were both essential and chokepoints were filtered in order to remove 6 
targets that could produce unwanted side effects. This analysis identified 413 essential 7 
metabolites, 554 chokepoints and a final list of 364 putative drug targets in M. 8 
tuberculosis. Chorismate synthesis was identified by this analysis as a broad range target. 9 
Chorismate is a key intermediate in the biosynthesis of a wide range of compounds, 10 
including aromatic amino acids, folate cofactors, menaquinones, ubiquinones, and 11 
siderophores. As a product of the shikimate pathway which is essential in higher plants, 12 
fungi, bacteria (including M. tuberculosis) and algae and is absent in mammals 13 
chorismate production has been validated as a drug target by others 42,43. The shikimate 14 
pathway is essential for the growth of M. tuberculosis even with exogenous 15 
supplementation with amino acids 44 and is therefore a very attractive anti-mycobacterial 16 
drug target. Mycolate synthesis was also identified as a prioritized drug target and its 17 
metabolism is already targeted by current anti-tubercular drugs.   18 
In another study drug target combinations were identified using an iNj661 based reaction 19 
influence network in order to analyze the dependency of one protein on another by virtue 20 
of metabolite sharing 45. Highly influential proteins (those which are linked to a large 21 
number of other proteins through metabolite sharing) in the network were identified and 22 
their interaction with other influential proteins analyzed in order to ascertain influential 23 
pairs, triplets and quadruplets. This analysis was complemented with FBA which 24 
demonstrated that most of the identified combinations of proteins are also synthetic 25 
lethals in silico and may therefore be very good drug targets. Multi-target therapeutics 26 
can be more efficacious and less vulnerable to adaptive resistance because the biological 27 
system is less able to compensate for the action of two or more drugs simultaneously; and 28 
is of course the standard treatment for tuberculosis. 29 
 16 
Another promising application of systems biology approaches in the drug discovery 1 
process is in the simulation of therapeutic intervention.  By developing a combined model 2 
consisting of enzyme inhibition kinetics, metabolic simulation by FBA of iNj661 and cell 3 
growth dynamics Fang et al, (2009) successfully simulated drug inhibition of M. 4 
tuberculosis. Two metabolic inhibitors 3-nitropropionate and 5’-O-(N-salicylsulfamoyl) 5 
adenosine which target the enzyme isocitrate lyase and salicyl-AMP ligase respectively 6 
were chosen to test the model as these have been identified as important targets for 7 
therapeutic intervention and experimental data is also available for these inhibitors46. The 8 
validation analysis showed that the model had good predictivity at determining the 9 
experimental dose response curve of both these drugs. A limitation to this study was that 10 
there was some overlap between the experimental data used for construction and 11 
validation of this model. However, this study demonstrates the successful integration of 12 
three different phenotypic components, a key strength of systems biology approaches 47.  13 
Future challenges 14 
The current models of M. tuberculosis metabolism are heavily influenced by the genome 15 
annotation, which, as we have already discussed, is likely to have many errors and is 16 
incomplete in many pathways. Inconsistencies between model predictions and 17 
experimental data are already apparent and indicate that there is much that remains to be 18 
learnt about the metabolism of this important pathogen.   19 
A key question is how M. tuberculosis actually catabolises its substrates and makes 20 
biomass both in vitro and in vivo. Although clues can be gleaned from the methods 21 
described above even FBA-based methods are hugely underdetermined so a great number 22 
of flux solutions are usually compatible with available data. The most powerful currently 23 
available method for directly measuring internal fluxes is 13C-MFA (Fig. 4). In this 24 
method, an organism is grown with a 13C-labelled substrate. The label is incorporated into 25 
internal metabolites and products of central metabolism, such as the proteogenic amino 26 
acids. The positional labeling patterns (which carbon atoms are labeled) of the amino 27 
acids and/or metabolites (as determined by either mass spectrometry or NMR) are then 28 
used as additional constraints in MFA to solve the internal fluxes and thereby reconstruct 29 
 17 
the paths through central metabolism that the carbon took inside the cells (Fig. 4). 13C-1 
MFA has already proved to be an invaluable tool in metabolic engineering and has been 2 
used to successfully identify novel or unusual pathways in bacteria 48,49 and has enormous 3 
potential for studying the metabolism of M. tuberculosis. In particular 13C-MFA could be 4 
used to investigate the metabolism of M. tuberculosis under conditions relevant to the in 5 
vivo situation such as low oxygen or using fatty acids as carbon sources. Such 6 
experiments could help answer questions surrounding the operation of the TCA cycle and 7 
may also identify entirely novel or unusual pathways in operation during these conditions 8 
which maybe prone to inhibition by targeted chemotherapy.   9 
Currently it is not possible to apply many of the tools of systems biology directly to 10 
examine the metabolism of M. tuberculosis in vivo due to the requirement for steady state 11 
growth conditions for stoichiometry-based modeling approaches (FBA and MFA) and the 12 
problems associated with separating the metabolism of the bacterium from that of the 13 
host. There are however developments being made in this area and it is expected that 14 
studying host pathogen interactions on a systems scale will eventually be possible 49.  The 15 
development of kinetic models would allow the application of modeling approaches to 16 
study of dynamic systems, such as infection, but, as discussed above, measuring 17 
parameters for such models remains a major challenge. For now, it appears that the best 18 
approach may be to utilize a combination of both in vitro and in vivo studies; utilizing the 19 
in vitro studies to develop mapping rules that can be applied to the more limited data 20 
available in vivo and thereby discover the answer to vitally important questions, such as 21 
what and how M. tuberculosis eats in vivo.  22 
The principle challenge for systems biology of M. tuberculosis is to construct more 23 
complete models that integrate genome, transcriptome, proteome, metabalome, 24 
physiology and structure and interactions with the host. Such multilevel models are 25 
beyond current capabilities but there are already models of transcriptional networks 38 26 
that could be integrated with metabolic models. Also, metabolic models of human cells 27 
have been constructed  7,50 which should soon allow the building of combined host-28 
pathogen cellular models that incorporate at least metabolite exchange between pathogen 29 
and host cell. While fully integrated models of tuberculosis are still a very distant goal, 30 
 18 
systems biology efforts can (and are beginning to) have an enormous impact on both our 1 
understanding of the metabolic potential of M. tuberculosis and the success of the drug 2 
discovery process which could lead to significant advances in the treatment of 3 
tuberculosis.   4 
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Figures 2 
Fig. 1. The iterative process of modeling the metabolism of the pathogen Mycobacterium 3 
tuberculosis. A cycle of model building and experimental validation, refinement of the 4 
model for the identification of drug targets and hypothesis generation is shown. The 5 
drawing includes the properties of the two available genome scale models 28,29. 6 
Fig. 2. A metabolic map of central metabolism in M. tuberculosis showing the reactions 7 
surrounding the TCA cycle. The standard TCA cycle is shown in blue with the variant 8 
(SSA) pathway in yellow. Anaplerotic/gluconeogenic reactions are shown in turquoise 9 
with the glyoxylate shunt in red. Only enzymes mentioned in the text are indicated, 10 
including KOR (α-ketoglutarate ferredoxin oxireductase), KGD (α-ketoglutarate 11 
decarboxylase), GabD1/D2 (succinic semialdehyde dehydrogenase), ICL (isocitrate 12 
lyase) and MEZ (malic enzyme (malate dehydogenase, decarboxylating)), PEPCK 13 
(phosphoenolpyruvate carboxykinase), PK (pyruvate kinase) and PYC (pyruvate 14 
carboxylase). 15 
Fig. 3. Flux variance analysis predicted an increased flux through the reaction catalysed 16 
by isocitrate lyase when M. tuberculosis is growing slowly in carbon limited conditions. 17 
Using the GSMN-TB we compared the predicted flux ratios for two different growth 18 
rates. A doubling time of 23 hours (dilution rate 0.03) was compared with a doubling 19 
time of 69 hours (dilution rate 0.01). Flux ratios for central metabolism were calculated 20 
by flux variability analysis (FVA) as the ratios of midpoints of flux ranges obtained for 21 
slow and fast growth rates. There was a large predicted (seven-fold) increase in flux 22 
through the isocitrate lyase reaction. This hypothesis was confirmed by experimentally 23 
demonstrating a significant increased specific isocitrate lyase activity in slow growing 24 
cells.  25 
Fig. 4 An experimental work flow for 13C Metabolic Flux Analysis (MFA). Media 26 
containing a mixture of unlabelled and labeled substrate is fed into steady state chemostat 27 
cultures. The label becomes distributed throughout the cells and after several volume 28 
 20 
changes the culture will reach isotopic steady state after which very little change to the 1 
labeling pattern will occur. Samples are taken for physiological measurements such as 2 
glycerol uptake rates and for measurement of the 13C enrichment of proteogenic amino 3 
acids from cell hydrolysates and sometimes also intracellular metabolite pools. An 4 
isotopomer model detailing the fate of each carbon atom in central metabolism is 5 
constructed and the experiment is simulated in silico. An algorithmic fitting procedure is 6 
used to adjust the fluxes in the isotopomer model to find the values of the intracellular 7 
fluxes that are consistent with the pattern of amino acid labeling.  8 
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